Conference Coverage
S6.7.2 – Newsmaker: Patient Advocate Jose Willemse on Drug Screening in Amsterdam and Patient-Centered Care
This week’s Newsmaker is Dutch Liver Patients Association President Jose Willemse. She discusses the patient screening program at the EASL Congress 2025 and the general idea of patient-sensitive dialogue with treaters.
S6.7 – Barcelona SLD Conference Highlight: NITs in Drug Development
This episode includes a discussion on patient management and self-management from the Global Think-Thank on Steatotic Liver Disease plus a segment from April’s Drug Development roundtable focusing on NITs in clinical trials. This week’s Newsmaker is Jose Willemse, President of the Dutch Liver Patients Association.
S5 – E24.4 – EASL Congress Six Weeks Later: Jeff McIntyre’s Key Implications for GLI
In the second half of Roger Green’s interview with Global Liver Institute Vice President, Liver Programs Jeff McIntyre, Jeff discusses the implications of his key EASL Congress takeaways for GLI and other patient advocacy groups.
S5-E24.3 – EASL Congress Six Weeks Later: Jeff McIntyre’s Key Takeaways
Global Liver Institute Vice President of Liver Programs Jeff McIntyre joins Roger Green to discuss what he considers key takeaways for GLI from EASL Congress 2024.
S5-E24.2 – EASL Congress Six Weeks Later: Mathieu Petitjean’s Key Implications
PharmaNest Founder and CEO Mathieu Petitjean joins Roger Green to discuss key implications for his business from what he learned at EASL Congress 2024.
S5-E24.1 – EASL Congress Six Weeks Later: Mathieu Petitjean’s Key Takeaways
PharmaNest Founder and CEO Mathieu Petitjean joins Roger Green to discuss key takeaways for his business from EASL Congress 2024.
S5-E24 – A View of MASLD: Looking Back at EASL Congress From Six Weeks Later
PharmaNest Founder and CEO Mathieu Petitjean and Global LIver Institute Vice President of Liver Programs Jeff McIntyre join Roger Green for 1:1 interviews exploring their key takeaways and strategic shifts resulting from the EASL Congress 2024, followed by a review of answers to a previous Question of the Week.
S5-SPECIAL 5 – Remembering EASL Congress – Louise Campbell 3 (first-time material)
Roger Green speaks with SurfingMASH co-host and Tawazun Health Founder and Clinical Director Louise Campbell on the last day of the EASL Congress. Their conversation focuses on how practice patterns, guidelines and training might change over the next few years.
S5 SPECIAL 4 – Reviewing EASL Congress: Sven Francque
Roger Green speaks with Hepatology Key Opinion Leader and EASL Educational Councillor Sven Francque 90 minutes after the EASL Congress closed. The discussion covers Clinical Practice Guidelines, drug development and NITs.
S5 SPECIAL 3 – Reviewing EASL Congress: Louise Campbell 2
Roger Green speaks with SurfingMASH co-host and Tawazun Health Founder and Clinical Director Louise Campbell on the last day of the EASL Congress. The discussion covers Clinical Practice Guidelines, drug development and NITs.
S5 SPECIAL 2 – Reviewing EASL Congress: Louise Campbell I
Roger Green speaks with SurfingMASH co-host and Tawazun Health Founder and Clinical Director Louise Campbell on the first day of the EASL Congress. The discussion includes the Patient Advocacy session co-chaired by Mike Betel and Shira Zelber-Sagi and several other presentations she attended.
S5 SPECIAL 1 – Reviewing EASL Congress: Mike Betel
Roger Green speaks with Fatty Liver Alliance Founder and CEO Mike Betel on the day before the EASL Congress officially opens. The discussion includes sessions Mike attended and one he co-chaired with Shira Zelber-Sagi, which is covered in Season 5 Episode 23.
S5-E23.4 – From the EASL Congress: Socioeconomic And Psychological Issues In The Physician-Patient Dialogue
Four panelists from the EASL Congress session on “Patient Experiences in Clinical Settings” join Louise Campbell to how socioeconomic and psychological issues can affect the physician-patient dialogue.
S5-E23.3 – From the EASL Congress: Improving the Physician-Patient Dialogue
Four panelists from the EASL Congress session on “Patient Experiences in Clinical Settings” join Louise Campbell to discuss ways to improve information sharing in the physician-patient dialogue.
S5-E23.2 – From the EASL Congress: Dynamics of the Physician-Patient Dialogue
Four panelists from the EASL Congress session on “Patient Experiences in Clinical Settings” join Louise Campbell to discuss some dynamics of the physician-patient dialogue.
S5-E23.1 – From the EASL Congress: Overview of Challenges in Physician-Patient Communication
This conversation with Louise Campbell and four panelists from the EASL Congress session titled “Patient Experiences in Clinical Settings” provides an overview of issues in physician-patient communication.
S5-E23 – Lessons from EASL Congress: Challenges in Provider-Patient Communication
Louise Campbell leads a discussion about challenges in provider-patient communication with Shira Zelber-Sagi and Mike Betel, who chaired a session on this topic at the EASL Congress 2024, and Tom Marjot and Jose Willemse, who were panelists for the discussion.
S5 – E22.5 – Healthy Livers, Healthy Lives: Watershed Moments To Come In MASLD Public Policy
Jeff Lazarus and the Surfers discuss the upcoming UN event for “Healthy Livers, Healthy Lives,” focusing on MASLD awareness. They explore challenges in educating policymakers, strategies for highlighting MASLD’s impact, and ways listeners can support the initiative.
S2-E22.4 – Healthy Livers, Healthy Lives: The Role of the Updated EASL MASLD Guidelines and Big Data
Healthy Livers, Healthy Lives Chair Jeff Lazarus and the Surfers discuss the value of the updated EASL/EASD/EASO MASLD clinical practice guidelines and explore the role of Big Data in early MASLD screening.
S5 – E22.3 – Healthy Livers, Healthy Lives: Challenges and Promise in Building a Global MASLD Health Policy
Healthy Livers, Healthy Lives Chair Jeff Lazarus and the Surfers discuss some specific challenges in building global MASLD policy and some local successes.
S5-E22.2 – Healthy Livers, Healthy Lives: “Political Will” in MASLD Public Policy
Healthy Livers, Healthy Lives’ Chair Jeff Lazarus shares with the Surfers the importance of political will in building a consensus for global MASLD public health policy.
S5-E22.1 – Healthy Livers, Healthy Lives: Why MASHville Needs This Coalition
In this opening conversation, Healthy LIvers, Healthy Lives Chair Jeff Lazarus discusses the goals of the coalition and two initiative to increase early screening.
S5 – E22 – Healthy Livers, Healthy Lives: A Global SLD Public Health Coalition
Jeff Lazarus, Chair of Healthy Livers, Healthy Lives, joins the Surfers to discuss this global SLD Public Health coalition. and the role of “top-down” solutions.
S5 – E21.5 – The Updated MASLD CPG: Implications For Healthcare Systems
In this closing conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi and podcast co-hosts Louise Campbell and Roger Green consider what the guidelines might foretell in changes in provider education, structure of patient visits and treatment in less affluent or medically advanced countries.
S5 – E21.4 – The Updated MASLD CPG: Pharmacology And New Educational Needs
For most of this conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi discuss key issues related to pharmacology and prescribing choices. At the end, the focus shifts to the guidelines’ overall benefits and some new kinds of education they call for.
S5 – E21.3 – The Updated MASLD CPG: Screening, Diagnosing And Managing Patients
In this conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi discuss some of the guidelines’ key goals and issues surrounding the screening, diagnosis and management of MASLD patients.
S5 – E21.2 – The Updated MASLD CPG: Benefits Of The Collaboration
In this conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi explain how the guidelines process benefitted from the close collaboration between EASL, EASD, and EASO.
S5 – E21.1 – The Updated MASLD CPG: Introductions
Two of the co-authors of the upgraded MASLD Clinical Practice Guidelines (CPG), Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to discuss the guidelines.
S5-E21 – Reviewing the Updated ESL-EASD-EASO MASLD Clinical Practice Guidelines
Co-authors Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to discuss the new MASLD Clinical Practice Guidelines from EASL, EASDand EASO.
S5-E20.5 – Drug Development Highlights From EASL Congress 2024: Denifenstat, SPECIAL & Other Stories
This conversation covers some of the other major drug development stories from the EASL Congress 2024, with special focus on denifenstat, ION-224 and TAK-227, plus a look at the SPECIAL study on bariatric surgery and cirrhosis.
S5-E20.4 – Drug Development Highlights From EASL Congress 2024: Are FGF-21s Induction Therapy or a “MASH Cure”?
This conversation focuses on the role FGF-21s will play in long-term advanced fibrosis treatment: induction or long-term therapy?
S5-E20.3 – Drug Development Highlights From EASL Congress 2024: “Twin-Cretins” & Efruxifermin
This conversation explores issues regarding incretin agonists and discusses results from the efruxiermin late-breaker at the EASL Congress 2024.
S5-E20.2 – Drug Development Highlights From EASL Congress 2024: Tirzepatidate & Other “Twin-Cretins”
This conversation focuses on the tirzepatide late-breaker at the EASL Congress 2024 and broadens into a discussion of the other “Twin-cretins,” all of which are GLP-glucagon combinations.
S5-E20.1 – Drug Development Highlights from EASL Congress 2024: Resmetirom
This conversation from EASL Congress 2024 discusses some of the new research on resmetirom.
S5-E20 – Lessons from EASL Congress 2024: Exciting Advances in Drug Development
Naim Alkhouri and Mazen Noureddin join co-hosts Jörn Schattenberg and Roger Green to discuss the major drug development stories from the EASL Congress 2024.
S5-E19 – EASL Congress 2024: Interviews From a Seminal Meeting for MASLD & MASH
Roger Green conducts 1:1 interviews with Mike Betel, Louise Campbell and Sven Francque while they are at the EASL Congress 2024, discussing key issues related to MASLD
S5-E17.5 – Previewing EASL Congress 2024: Focusing on MASLD Drug Development
As the conversation wraps up, Jörn Schattenberg and Michelle Long discusses abstracts they will present at EASL Congress 2024, with Jörn focusing on new MASLD drug development and Michelle on an aggregation of studies sponsored by Novo Nordisk.
S5-E17.3 – Previewing EASL Congress 2024: Jörn Schattenberg Joins the MASLD Conversation
This conversation starts when co-host Jörn Schattenberg joins our EASL Congress 20224 preview. The episode itself focuses on the future of hepatology along with other MASLD abstracts and presentations.
S5-E17.2 – Previewing EASL Congress 2024: Collegiality, Consortia & High-Quality MASLD Abstracts
This conversation centers around two thoughts about the EASL Congress 2024 from Michelle Long.one on network value and the other on the reat benefit that comes from reviewing abstracts in advance.
S5-E17.1 – Previewing EASL Congress 2024: Secretary General Aleksander Krag Shares His Vision for the Congress
EASL Secretary General Aleksander Krag offers his vision for the EASL Congress 2024, after which Hannes Hagstrom shared some impressions.
S6.7.2 – Newsmaker: Patient Advocate Jose Willemse on Drug Screening in Amsterdam and Patient-Centered Care
This week’s Newsmaker is Dutch Liver Patients Association President Jose Willemse. She discusses the patient screening program at the EASL Congress 2025 and the general idea of patient-sensitive dialogue with treaters.
S6.7 – Barcelona SLD Conference Highlight: NITs in Drug Development
This episode includes a discussion on patient management and self-management from the Global Think-Thank on Steatotic Liver Disease plus a segment from April’s Drug Development roundtable focusing on NITs in clinical trials. This week’s Newsmaker is Jose Willemse, President of the Dutch Liver Patients Association.
S5-SPECIAL 5 – Remembering EASL Congress – Louise Campbell 3 (first-time material)
Roger Green speaks with SurfingMASH co-host and Tawazun Health Founder and Clinical Director Louise Campbell on the last day of the EASL Congress. Their conversation focuses on how practice patterns, guidelines and training might change over the next few years.
S5-E24.3 – EASL Congress Six Weeks Later: Jeff McIntyre’s Key Takeaways
Global Liver Institute Vice President of Liver Programs Jeff McIntyre joins Roger Green to discuss what he considers key takeaways for GLI from EASL Congress 2024.
S5-E24.2 – EASL Congress Six Weeks Later: Mathieu Petitjean’s Key Implications
PharmaNest Founder and CEO Mathieu Petitjean joins Roger Green to discuss key implications for his business from what he learned at EASL Congress 2024.
S5-E24.1 – EASL Congress Six Weeks Later: Mathieu Petitjean’s Key Takeaways
PharmaNest Founder and CEO Mathieu Petitjean joins Roger Green to discuss key takeaways for his business from EASL Congress 2024.